{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:21:04Z","timestamp":1790706064372,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T00:00:00Z","timestamp":1636070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T00:00:00Z","timestamp":1636070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This study evaluated the risk of medication-related osteonecrosis of the jaw (MRONJ) in patients with cancer who received denosumab or zoledronic acid (ZA) for treating bone metastasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The medical records of patients were retrospectively reviewed. Patients who did not undergo a dental examination at baseline were excluded. The primary endpoint was a comparison of the risk of developing MRONJ between the denosumab and ZA groups. Propensity score matching was used to control for baseline differences between patient characteristics and compare outcomes for both groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among the 799 patients enrolled, 58 (7.3%) developed MRONJ. The incidence of MRONJ was significantly higher in the denosumab group than in the ZA group (9.6% [39\/406] vs. 4.8% [19\/393],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.009). Multivariate Cox proportional hazards regression analysis revealed that denosumab treatment (hazard ratio [HR], 2.89; 95% confidence interval [CI], 1.65\u20135.25;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and tooth extraction after starting ZA or denosumab (HR, 4.26; 95% CI, 2.38\u20137.44;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) were significant risk factors for MRONJ. Propensity score\u2013matched analysis confirmed that the risk of developing MRONJ was significantly higher in the denosumab group than in the ZA group (HR, 2.34; 95% CI, 1.17\u20135.01;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.016).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The results of this study suggest that denosumab poses a significant risk for developing MRONJ in patients treated for bone metastasis, and thus these patients require close monitoring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00520-021-06634-7","type":"journal-article","created":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T00:19:11Z","timestamp":1636071551000},"page":"2341-2348","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score\u2013matched analysis"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8499-131X","authenticated-orcid":false,"given":"Hiroaki","family":"Ikesue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Doi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayu","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Hirabatake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Muroi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Takenobu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Hashida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,5]]},"reference":[{"key":"6634_CR1","doi-asserted-by":"publisher","first-page":"4081","DOI":"10.1007\/s00520-020-05880-5","volume":"29","author":"G Saito","year":"2021","unstructured":"Saito G, Ebata T, Ishiwata T, Iwasawa S, Yoshino I, Takiguchi Y, Tatsumi K (2021) Risk factors for skeletal-related events in non-small cell lung cancer patients treated with bone-modifying agents. Support Care Cancer 29:4081\u20134088","journal-title":"Support Care Cancer"},{"key":"6634_CR2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ctrv.2019.05.003","volume":"76","author":"R von Moos","year":"2019","unstructured":"von Moos R, Costa L, Gonzalez-Suarez E, Terpos E, Niepel D, Body JJ (2019) Management of bone health in solid tumours: from bisphosphonates to a monoclonal antibody. Cancer Treat Rev 76:57\u201367","journal-title":"Cancer Treat Rev"},{"key":"6634_CR3","doi-asserted-by":"publisher","first-page":"546","DOI":"10.3390\/cancers13030546","volume":"13","author":"V Mollica","year":"2021","unstructured":"Mollica V, Rizzo A, Rosellini M, Marchetti A, Ricci AD, Cimadamore A et al (2021) Bone targeting agents in patients with metastatic prostate cancer: state of the art. Cancers 13:546","journal-title":"Cancers"},{"key":"6634_CR4","doi-asserted-by":"crossref","unstructured":"Link H, Diel I, Ohlmann CH, Holtmann L, Kerkmann M; Associations Supportive Care in Oncology (AGSMO), Medical Oncology (AIO), Urological Oncology (AUO), within the German Cancer Society (DKG) and the German Osteooncological Society (DOG) (2020) Guideline adherence in bone-targeted treatment of cancer patients with bone metastases in Germany. Support Care Cancer 28:2175\u20132184","DOI":"10.1007\/s00520-019-05018-2"},{"key":"6634_CR5","doi-asserted-by":"crossref","unstructured":"Coleman R, Body JJ, Aapro M, Hadji P, Herrstedt J, ESMO Guidelines Working Group (2014) Bone health in cancer patients: ESMO clinical practice guidelines. Ann Oncol 25: iii124\u2013137","DOI":"10.1093\/annonc\/mdu103"},{"key":"6634_CR6","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","volume":"383","author":"YL Wu","year":"2020","unstructured":"Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M et al (2020) Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med 383:1711\u20131723","journal-title":"N Engl J Med"},{"key":"6634_CR7","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41572-020-00216-3","volume":"6","author":"RE Coleman","year":"2020","unstructured":"Coleman RE, Croucher PI, Padhani AR, Cl\u00e9zardin P, Chow E, Fallon M et al (2020) Bone metastases Nat Rev Dis Primers 6:83","journal-title":"Bone metastases Nat Rev Dis Primers"},{"key":"6634_CR8","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","volume":"383","author":"RS Herbst","year":"2020","unstructured":"Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH et al (2020) Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N Engl J Med 383:1328\u20131339","journal-title":"N Engl J Med"},{"key":"6634_CR9","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1056\/NEJMoa2001342","volume":"383","author":"K Fizazi","year":"2020","unstructured":"Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S et al (2020) Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. N Engl J Med 383:1040\u20131049","journal-title":"N Engl J Med"},{"key":"6634_CR10","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S1470-2045(19)30687-4","volume":"21","author":"R Coleman","year":"2020","unstructured":"Coleman R, Finkelstein DM, Barrios C, Martin M, Iwata H, Hegg R et al (2020) Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 21:60\u201372","journal-title":"Lancet Oncol"},{"key":"6634_CR11","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1001\/jamaoncol.2019.4636","volume":"6","author":"AJ Armstrong","year":"2020","unstructured":"Armstrong AJ, Al-Adhami M, Lin P, Parli T, Sugg J, Steinberg J et al (2020) Association between new unconfirmed bone lesions and outcomes in men with metastatic castration-resistant prostate cancer treated with enzalutamide: secondary analysis of the PREVAIL and AFFIRM randomized clinical trials. JAMA Oncol 6:217\u2013225","journal-title":"JAMA Oncol"},{"key":"6634_CR12","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s00520-020-05556-0","volume":"29","author":"TL Ng","year":"2020","unstructured":"Ng TL, Tu MM, Ibrahim MFK, Basulaiman B, McGee SF, Srikanthan A et al (2020) Long-term impact of bone-modifying agents for the treatment of bone metastases: a systematic review. Support Care Cancer 29:925\u2013943","journal-title":"Support Care Cancer"},{"key":"6634_CR13","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1002\/jbmr.5650090521","volume":"9","author":"JR Green","year":"1994","unstructured":"Green JR, M\u00fcller K, Jaeggi KA (1994) Preclinical pharmacology of CGP 42\u2019446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 9:745\u2013751","journal-title":"J Bone Miner Res"},{"key":"6634_CR14","doi-asserted-by":"publisher","first-page":"3597","DOI":"10.1073\/pnas.95.7.3597","volume":"95","author":"H Yasuda","year":"1998","unstructured":"Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S et al (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin\/osteoclastogenesis-inhibitory factor and is identical to TRANCE\/RANKL. Proc Natl Acad Sci USA 95:3597\u20133602","journal-title":"Proc Natl Acad Sci USA"},{"key":"6634_CR15","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1177\/1060028014539919","volume":"48","author":"H Ikesue","year":"2014","unstructured":"Ikesue H, Tsuji T, Hata K, Watanabe H, Mishima K, Uchida M et al (2014) Time course of calcium concentrations and risk factors for hypocalcemia in patients receiving denosumab for the treatment of bone metastases from cancer. Ann Pharmacother 48:1159\u20131165","journal-title":"Ann Pharmacother"},{"key":"6634_CR16","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","volume":"61","author":"RE Marx","year":"2003","unstructured":"Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115\u20131117","journal-title":"J Oral Maxillofac Surg"},{"key":"6634_CR17","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1200\/JCO.19.01186","volume":"37","author":"N Yarom","year":"2019","unstructured":"Yarom N, Shapiro CL, Peterson DE, Van Poznak CH, Bohlke K, Ruggiero SL et al (2019) Medication-related osteonecrosis of the jaw: MASCC\/ISOO\/ASCO clinical practice guideline. J Clin Oncol 37:2270\u20132290","journal-title":"J Clin Oncol"},{"key":"6634_CR18","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s00774-016-0810-7","volume":"35","author":"T Yoneda","year":"2017","unstructured":"Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S et al (2017) Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw. J Bone Miner Metab 35:6\u201319","journal-title":"J Bone Miner Metab"},{"key":"6634_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jbmr.2405","volume":"30","author":"AA Khan","year":"2015","unstructured":"Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O\u2019Ryan F et al (2015) Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 30:3\u201323","journal-title":"J Bone Miner Res"},{"key":"6634_CR20","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","volume":"72","author":"SL Ruggiero","year":"2014","unstructured":"Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B et al (2014) American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw\u20132014 update. J Oral Maxillofac Surg 72:1938\u20131956","journal-title":"J Oral Maxillofac Surg"},{"key":"6634_CR21","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.3390\/cancers12051209","volume":"12","author":"S Okuma","year":"2020","unstructured":"Okuma S, Matsuda Y, Nariai Y, Karino M, Suzuki R, Kanno TA (2020) A retrospective observational study of risk factors for denosumab-related osteonecrosis of the jaw in patients with bone metastases from solid cancers. Cancers 12:1209","journal-title":"Cancers"},{"key":"6634_CR22","doi-asserted-by":"publisher","first-page":"4019","DOI":"10.1007\/s00520-020-05440-x","volume":"28","author":"L Drudge-Coates","year":"2020","unstructured":"Drudge-Coates L, Van den Wyngaert T, Schi\u00f8dt M, van Muilekom HAM, Demonty G, Otto S (2020) Preventing, identifying, and managing medication-related osteonecrosis of the jaw: a practical guide for nurses and other allied healthcare professionals. Support Care Cancer 28:4019\u20134029","journal-title":"Support Care Cancer"},{"key":"6634_CR23","first-page":"e326","volume":"25","author":"A Limones","year":"2020","unstructured":"Limones A, S\u00e1ez-Alcaide LM, D\u00edaz-Parre\u00f1o SA, Helm A, Bornstein MM, Molinero-Mourelle P (2020) Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab vs. zoledronic acid: a systematic review and meta-analysis. Med Oral Patol Oral Cir Bucal 25:e326\u2013e336","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"6634_CR24","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1159\/000447372","volume":"39","author":"F Chen","year":"2016","unstructured":"Chen F, Pu F (2016) Safety of denosumab versus zoledronic acid in patients with bone metastases: a meta-analysis of randomized controlled trials. Oncol Res Treat 39:453\u2013459","journal-title":"Oncol Res Treat"},{"key":"6634_CR25","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","volume":"23","author":"F Saad","year":"2012","unstructured":"Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT et al (2012) Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 23:1341\u20131347","journal-title":"Ann Oncol"},{"key":"6634_CR26","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","volume":"48","author":"A Lipton","year":"2012","unstructured":"Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA et al (2012) Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 48:3082\u20133092","journal-title":"Eur J Cancer"},{"key":"6634_CR27","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1007\/s00520-010-1061-0","volume":"19","author":"T Van den Wyngaert","year":"2011","unstructured":"Van den Wyngaert T, Wouters K, Huizing MT, Vermorken JB (2011) RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ): non bis in idem? Support Care Cancer 19:2035\u20132040","journal-title":"Support Care Cancer"},{"key":"6634_CR28","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1016\/j.joms.2009.07.097","volume":"67","author":"G Colella","year":"2009","unstructured":"Colella G, Campisi G, Fusco V (2009) American Association of Oral and Maxillofacial Surgeons position paper: Bisphosphonate-related osteonecrosis of the jaws-2009 update: the need to refine the BRONJ definition. J Oral Maxillofac Surg 67:2698\u20132699","journal-title":"J Oral Maxillofac Surg"},{"key":"6634_CR29","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1093\/annonc\/mdm370","volume":"18","author":"F Jadu","year":"2007","unstructured":"Jadu F, Lee L, Pharoah M, Reece D, Wang L (2007) A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. Ann Oncol 18:2015\u20132019","journal-title":"Ann Oncol"},{"key":"6634_CR30","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3816\/CLM.2008.n.013","volume":"8","author":"AM Cafro","year":"2008","unstructured":"Cafro AM, Barbarano L, Nosari AM, D\u2019Avanzo G, Nichelatti M, Bibas MO (2008) Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: definition and management of the risk related to zoledronic acid. Clin Lymphoma Myeloma 8:111\u2013116","journal-title":"Clin Lymphoma Myeloma"},{"key":"6634_CR31","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/annonc\/mdn526","volume":"20","author":"CI Ripamonti","year":"2009","unstructured":"Ripamonti CI, Maniezzo M, Campa T, Fagnoni E, Brunelli C, Saibene G et al (2009) Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 20:137\u2013145","journal-title":"Ann Oncol"},{"key":"6634_CR32","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","volume":"28","author":"AT Stopeck","year":"2010","unstructured":"Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH et al (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28:5132\u20135139","journal-title":"J Clin Oncol"},{"key":"6634_CR33","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","volume":"377","author":"K Fizazi","year":"2011","unstructured":"Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L et al (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377:813\u2013822","journal-title":"Lancet"},{"key":"6634_CR34","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","volume":"29","author":"DH Henry","year":"2011","unstructured":"Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J et al (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29:1125\u20131132","journal-title":"J Clin Oncol"},{"key":"6634_CR35","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1248\/bpb.b15-00385","volume":"38","author":"M Kajizono","year":"2015","unstructured":"Kajizono M, Sada H, Sugiura Y, Soga Y, Kitamura Y, Matsuoka J et al (2015) Incidence and risk factors of osteonecrosis of the jaw in advanced cancer patients after treatment with zoledronic acid or denosumab: a retrospective cohort study. Biol Pharm Bull 38:1850\u20131855","journal-title":"Biol Pharm Bull"},{"key":"6634_CR36","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00520-015-2904-5","volume":"24","author":"AT Stopeck","year":"2016","unstructured":"Stopeck AT, Fizazi K, Body JJ, Brown JE, Carducci M, Diel I et al (2016) Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. Support Care Cancer 24:447\u2013455","journal-title":"Support Care Cancer"},{"key":"6634_CR37","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","volume":"19","author":"N Raje","year":"2018","unstructured":"Raje N, Terpos E, Willenbacher W, Shimizu K, Garcia-Sanz R, Durie B et al (2018) Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol 19:370\u2013381","journal-title":"Lancet Oncol"},{"key":"6634_CR38","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1016\/j.clgc.2018.08.006","volume":"17","author":"A Guillot","year":"2019","unstructured":"Guillot A, Joly C, Barthelemy P, Meriaux E, Negrier S, Pouessel D et al (2019) Denosumab toxicity when combined with anti-angiogenic therapies on patients with metastatic renal cell carcinoma: a GETUG study. Clin Genitourin Cancer 17:e38\u2013e43","journal-title":"Clin Genitourin Cancer"},{"key":"6634_CR39","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1007\/s00520-019-05044-0","volume":"28","author":"AL Soares","year":"2020","unstructured":"Soares AL, Simon S, Gebrim LH, Nazario ACP, Lazaretti-Castro M (2020) Prevalence and risk factors of medication-related osteonecrosis of the jaw in osteoporotic and breast cancer patients: a cross-sectional study. Support Care Cancer 28:2265\u20132271","journal-title":"Support Care Cancer"},{"key":"6634_CR40","doi-asserted-by":"publisher","first-page":"4763","DOI":"10.1007\/s00520-021-06018-x","volume":"29","author":"H Ikesue","year":"2021","unstructured":"Ikesue H, Mouri M, Tomita H, Hirabatake M, Ikemura M, Muroi N, Yamamoto S, Takenobu T, Tomii K, Kawakita M, Katoh H, Ishikawa T, Yasui H, Hashida T (2021) Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases. Support Care Cancer 29:4763\u20134772","journal-title":"Support Care Cancer"},{"key":"6634_CR41","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s00774-020-01151-9","volume":"39","author":"Y Nakai","year":"2020","unstructured":"Nakai Y, Kanaki T, Yamamoto A, Tanaka R, Yamamoto Y, Nagahara A et al (2020) Antiresorptive agent-related osteonecrosis of the jaw in prostate cancer patients with bone metastasis treated with bone-modifying agents. J Bone Miner Metab 39:295\u2013301","journal-title":"J Bone Miner Metab"},{"key":"6634_CR42","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.oooo.2020.04.808","volume":"130","author":"F Hallmer","year":"2020","unstructured":"Hallmer F, Bjarnadottir O, Gotrick B, Malmstrom P, Andersson G (2020) Incidence of and risk factors for medication-related osteonecrosis of the jaw in women with breast cancer with bone metastasis: a population-based study. Oral Surg Oral Med Oral Pathol Oral Radiol 130:252\u2013257","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"6634_CR43","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.oooo.2018.02.003","volume":"125","author":"AA Owosho","year":"2018","unstructured":"Owosho AA, Liang STY, Sax AZ, Wu K, Yom SK, Huryn JM et al (2018) Medication-related osteonecrosis of the jaw: an update on the Memorial Sloan Kettering Cancer Center experience and the role of premedication dental evaluation in prevention. Oral Surg Oral Med Oral Pathol Oral Radiol 125:440\u2013445","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"6634_CR44","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1111\/odi.13294","volume":"26","author":"O Nicolatou-Galitis","year":"2020","unstructured":"Nicolatou-Galitis O, Papadopoulou E, Vardas E, Kouri M, Galiti D, Galitis E et al (2020) Alveolar bone histological necrosis observed prior to extractions in patients, who received bone-targeting agents. Oral Dis 26:955\u2013966","journal-title":"Oral Dis"},{"key":"6634_CR45","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1111\/odi.13160","volume":"25","author":"M Schiodt","year":"2019","unstructured":"Schiodt M, Otto S, Fedele S, Bedogni A, Nicolatou-Galitis O, Guggenberger R et al (2019) Workshop of European Task Force on Medication-Related Osteonecrosis of the Jaw-current challenges. Oral Dis 25:1815\u20131821","journal-title":"Oral Dis"},{"key":"6634_CR46","doi-asserted-by":"publisher","unstructured":"Bacci C, Cerrato A, Bardhi E, Frigo AC, Djaballah SA, Sivolella SA (2021) Retrospective study on the incidence of medication-related osteonecrosis of the jaws (MRONJ) associated with different preventive dental care modalities. Support Care Cancer https:\/\/doi.org\/10.1007\/s00520-021-06587-x [online ahead of print]","DOI":"10.1007\/s00520-021-06587-x"},{"key":"6634_CR47","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/clr.12556","volume":"27","author":"A Boquete-Castro","year":"2016","unstructured":"Boquete-Castro A, G\u00f3mez-Moreno G, Calvo-Guirado JL, Aguilar-Salvatierra A, Delgado-Ruiz RA (2016) Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials. Clin Oral Implants Res 27:367\u2013375","journal-title":"Clin Oral Implants Res"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-021-06634-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-021-06634-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-021-06634-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T05:40:17Z","timestamp":1666762817000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-021-06634-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,5]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["6634"],"URL":"https:\/\/doi.org\/10.1007\/s00520-021-06634-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-693498\/v1","asserted-by":"object"}]},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,5]]},"assertion":[{"value":"8 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. The protocol was approved by the Ethics Committee of Kobe City Medical Center General Hospital (approval number: k191010). Due to the retrospective nature of this work, the research plan was published on the homepage of the hospital according to the instructions of the Ethics Committee in accordance with the guaranteed opt-out opportunity.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}